Cymabay Therapeutics, Inc. (NASDAQ:CBAY) Hits Highs with Strength in Pipeline

Cymabay Therapeutics, Inc. (NASDAQ:CBAY)

Cymabay Therapeutics, Inc. (NASDAQ:CBAY) was upgraded by H.C. Wainwright from “Neutral” to “Buy” at the end of January. However CBAY had already delivered some spectacular performance prior to that announcement. Last week CBAY shares gained over 37%, and YTD the stock is up over 85%. On Friday shares gained over 15%, on four times their average daily volumes, and the Relative Strength Indicator (RSI) was sitting at over 85 – overbought by most standards. Still, analysts have a price target of over $5.65 on CBAY.

SanFancisco, CA-based Cymabay Therapeutics, Inc. (NASDAQ:CBAY) is a clinical-stage biopharmaceutical company that develops therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) was seeded with the assets from an earlier biotechnology company that had a pipeline which was the result of over $120 million in development expenses. Their pipeline is more mature than many other firms in the biotech space.


According to the centers for Disease Control, 8.3 million U.S. adults are afflicted by this disease and gout’s prevalence grew by 1.2% over the previous two decades. MBX-8025 addresses aspects of metabolic syndrome, including improvements in insulin sensitivity and trends toward decreased waist circumference and body fat. Over half of the patients that entered the Phase 2 study meeting the criteria for metabolic syndrome no longer met the criteria at the end of the study. MBX-2982 demonstrated dose-dependent increases in drug exposure with a profile supporting once daily oral dosing that was safe and well tolerated with no serious adverse events, adverse event trends or dose-limiting toxicities. These results may provide clinical validation for the potential therapeutic benefits of MBX-2982 as a type 2 diabetes treatment.

Three firms follow Cymabay Therapeutics, Inc. (NASDAQ:CBAY) – one rates CAY as a “Buy”, while the other two rate the shares as a “Strong Buy”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol CBAY
Last Price a/o 8:00 PM EST  $                      3.24
Average Volume                    402,850
Market Cap (mlns)  $                    75.73
Sales (mlns) $0.00
Shares Outstanding (mlns) 23.45
Share Float (mlns) 23.13
Shortable Yes
Optionable No
Inside Ownership 0.10%
Short Float 1.53%
Short Interest Ratio 0.88
Quarterly Return 57.56%
YTD Return 86.71%
Year Return 180.87%

Fate Therapeutics, Inc. (NASDA:FATE) A Keeper?

Fate Therapeutics, Inc. (NASDAQ:FATE)

Fate Therapeutics, Inc. (NASDAQ:FATE) shares are up 15% on volumes exceeding 20 times their normal daily trading levels.

Fate Therapeutics, Inc. (NASDAQ:FATE) is a biopharmaceutical company that develops programmed cellular immunotherapies for cancer and immune disorders. The company’s pipeline includes NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cell lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Fate Therapeutics’ adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.


San Diego, CA-based Fate Therapeutics, Inc. (NASDAQ:FATE) received a patent in October of 2015. The patent was foundational to the generation of induced pluripotent cells, which are a source of cells offering unique potential for off-the-shelf adoptive immunotherapy. In December of 2015. Fate Therapeutics announced supportive data from the Company’s Phase 2 PUMA clinical trial of ProHema and provided an update on its therapeutic strategy for hematopoietic cell transplantation (HCT). The Company expected to initiate an open-label, randomized, controlled Phase 1 and 2 clinical trial of ProTmune in 2016 to investigate the potential of ProTmune to prevent acute graft-versus-host disease (GvHD) and severe viral infections in patients undergoing mobilized peripheral blood HCT. The Company also announced it would discontinue further development of ProHema in patients undergoing cord blood HCT.

In January of 2016 Fate Therapeutics, Inc. (NASDAQ:FATE) announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s investigational new drug application for ProTmune. At that time, Fate Therapeutics also announced plans to initiate a multi-center, randomized, controlled Phase 1/2 clinical trial in adult patients with hematologic malignancies undergoing mobilized peripheral blood (mPB) hematopoietic cell transplantation (HCT) in mid-2016. In June, 2016 the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ProTmune.

Fate Therapeutics Inc. (NASDAQ:FATE) then announced in September of 2016 a partnership with Memorial Sloan Kettering Cancer Center for the development of off-the-shelf T-cell product candidates using engineered pluripotent cell lines. Last month the company announced that the first patient has been treated in its PROTECT clinical trial of ProTmune for the prevention of acute graft-versus-host disease (GvHD).

The Numbers

In 2011 Fate Therapeutics Inc. (NASDAQ:FATE) reported sales of $1.2 million followed by annual sales of $2.7 million, $1.0 million, zero sales for 2014 and $2.4 million in sales for 2015. EPS for FATE shareholders has always been negative. In 2011 the EPS loss was $0.70 and a downward trend ended in 2014 when the company reported an EPS loss of $1.27. The loss was narrowed to -$1.18 in 2015. Six firms follow Fate Therapeutics Inc. (NASDAQ:FATE). One rates the shares a “Buy” and the others rate FATE as a “Strong Buy”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol FATE
Last Price a/o 10:24 AM EST  $                      3.95
Average Volume                    155,800
Market Cap (mlns)  $                  139.36
Sales (mlns) $4.50
Shares Outstanding (mlns) 41.11
Share Float (mlns) 40.55
Shortable Yes
Optionable No
Inside Ownership 0.50%
Short Float 0.84%
Short Interest Ratio 2.18
Quarterly Return 13.00%
YTD Return 35.06%
Year Return 117.31%

Neuralstem, Inc. (NASDAQ:CUR) Will Patent Help Share Performance?

Neuralstem, Inc. (NASDAQ:CUR)

Neuralstem, Inc. (NASDAQ:CUR) is a clinical stage biopharmaceutical company based in Germantown, MD. Neuralstem owns patented technology that enables commercial-scale production of multiple types of central nervous system stem cells which are under development for the potential treatment of central nervous system diseases and conditions.


Neuralstem, Inc. (NASDAQ:CUR) has completed Phase 1a and 1b trials evaluating NSI-189, its first neurogenic small molecule product candidate, for the treatment of major depressive disorder (MDD), and is expecting to initiate a Phase II study for MDD. Neuralstem’s first stem cell product candidate, NSI-566, a spinal cord-derived neural stem cell line, is under development for treatment of amyotrophic lateral sclerosis (ALS). Neuralstem has completed two clinical studies, in a total of thirty patients that met primary safety endpoints.

Neuralstem’s next generation stem cell product, NSI-532.IGF, consists of human cortex-derived neural stem cells that have been engineered to secrete human insulin-like growth factor 1 (IGF-1). In animal data presented at the Congress of Neurological Surgeons 2014 Annual Meeting, the cells rescued spatial learning and memory deficits in an animal model of Alzheimer’s disease.

On September 12, 2016, Neuralstem, Inc. (NASDAQ:CUR) announced the closing of Tianjin Pharmaceutical Group International Holdings Co., LTD.’s $20 million strategic investment. Tianjin receives 28,500,000 shares of common stock and 1,000,000 shares of Series A convertible preferred stock. The preferred stock is convertible into 50,551,383 shares of the company’s common stock subject to certain beneficial ownership limitations.

Yesterday, Neuralstem, Inc. (NASDAQ:CUR) announced completion of subject enrollment in its Phase 2 clinical trial of NSI-189 for the treatment of major depressive disorder (MDD). NSI-189 is a new chemical entity and the lead compound in Neuralstem’s neurogenic small molecule program. In a Phase 1b study, NSI-189 was shown to safely alleviate depression in patients with MDD. Enrollment was completed ahead of schedule and data are expected in 3Q 2017.

The Numbers

Neuralstem, Inc. (NASDAQ:CUR) went through a reverse (1:13) split on January 13, 2017. Adjusted for corporate actions, CUR was trading over $10 one year ago. Volumes had been light (<100,000) until January of 2017. Then on January 10, volumes exploded to over three million as the price of CUR gained almost 50% when Neuralstem, Inc. was awarded a patent for treating neurodegenerative diseases through the application of neural stem cells from spinal cord tissues.

Neuralstem, Inc. (NASDAQ:CUR) had sales of $400k in 2011 and 2012 but reported no sales in 2014 and 2015. The shareholders have experienced negative EPS since 2011 when CUR posted a loss of $3.37 which was followed in subsequent years by EPS losses of $2.26, $3.57, $3.38, and $2.99. Of the six firms that follow Neuralstem, Inc. (NASDAQ:CUR), five rate the shares as a “Hold” and one rates CUR as a “Sell”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol CUR
Last Price a/o 8:39 AM EST  $                      3.75
Average Volume                    555,500
Market Cap (mlns)  $                    40.95
Sales (mlns) $0.01
Shares Outstanding (mlns) 10.85
Share Float (mlns) 10.68
Shortable Yes
Optionable Yes
Inside Ownership 0.10%
Short Float 7.26%
Short Interest Ratio 1.4
Quarterly Return 0.00%
YTD Return 7.41%
Year Return -65.88%

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Worth the Risk?

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)

Israel-based XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company has two product candidates in clinical development. The first is CDR1 peptide is a novel compound, working via a novel mechanism of action, for the treatment of Systemic Lupus Erythematosus (“SLE”). hCDR1 has completed three clinical trials involving more than 400 patients. Recombinant Erythropoietin (rHuEPO) is a known compound the company is developing for the prolongation of multiple myeloma (MM) advanced-stage patients’ survival and improvement of their quality of life.


On January 5th, 2017 XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) announced that new in-vitro data from studies evaluating cells obtained from serum samples of patients with Sjögren’s syndrome demonstrate that incubation with hCDR1 resulted in a significant reduction of gene expression of three cytokines considered to be pathogenic in Sjögren’s syndrome.

On January 25th, 2017 the company announced a change in the ratio from one depositary share (DS) representing twenty ordinary shares to a new ratio of one DS representing one hundred ordinary shares. For the Company’s DS holders, this ratio change would have the same effect as a reverse split on the XTL DSs on the basis of one (1) new DS for every five (5) old DSs held.

On February 13, 2017 XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) announced that two leading experts in  rheumatology, Robert  Fox,  MD  and  Simon  Bowman,  MD,  joined  the Company’s  clinical  advisory board  to  help  guide  a planned  Phase  II  trial to  evaluate  the company’s investigational drug, hCDR1, for the treatment of Sjögren’s syndrome.

The Numbers

One year ago XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) was trading at $6. Today XTLB shares closed at $3.58. The company has no sales or earnings. HC Wainwright is the only firm that covers XTLB and rates the shares as a “Strong Buy”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Editas Medicine, Inc. (NASDAQ:EDIT) Move on USPTO Decision

Editas Medicine, Inc. (NASDAQ:EDIT)

Editas Medicine, Inc. (NASDAQ:EDIT) shares are up over 30% – including the after-hours trading action on 17 times normal average volumes. The catalyst was a decision by the U.S. Patent and Trademark Office (USPTO) that upheld a patent held by the Broad Institute and the Massachusetts’s Institute of Technology (MIT) concerning the gene editing technology CRISPR/Cas9. Editas Medicine, Inc. (NASDAQ:EDIT) was founded with the object of monetizing the patents. The losing parties in the dispute were the University of California at Berkley (UCB), and the biotech firms Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Crisper Therapeutics AG (NASDAQ:CRSP). Crisper and Intellia were also formed to monetize the patented technology.

The researchers at UCB are generally accepted as the discoverers of the CRISPR/Cas9 technology and, as one would expect, filed the patents. However, the Broad Institute filed for patent protection for the same technology based on their claim that researcher Fred Zhang was the “first to discover” that the technology could be used to edit genes in specific species. CRISPR/Cas9 technology can be used to more precisely edit DNA – supposedly the next big thing in Biotech.

The USPTO’s decision affected shares of all three companies immediately. Just before 1PM EST, news hit and Editas Medicine, Inc. (NASDAQ:EDIT) shares went from less than $19 to $22 in minutes. Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) experienced the opposite trajectory. Trading around $13.75 at 1PM EST, NTLA shares fell for the next hour and hit a low of $10.83 before recovering and settling at $12.51. Crisper Therapeutics AG (NASDAQ:CRSP) also were hit at the same time – dropping from around $17.35 to $11.63 before recovering and closing the regular session at $15.90.

Editas Medicine, Inc. (NASDAQ:EDIT) is followed by five firms. Three rate EDIT a “Strong Buy” and two rate the shares as a “Hold”. Undoubtedly, ratings will be reviewed given the recent USPTO decision.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol EDIT
Last Price a/o 5:27 PM EST  $                    24.80
Average Volume                    340,300
Market Cap (mlns)  $                  891.32
Sales (mlns) $5.90
Shares Outstanding (mlns) 36.68
Share Float (mlns) 30.99
Shortable Yes
Optionable Yes
Inside Ownership 7.90%
Short Float 9.04%
Short Interest Ratio 8.23
Quarterly Return 42.94%
YTD Return 49.72%
Year Return 45.51%

Evoke Pharma, Inc. (NASDAQ: EVOK) Pops On FDA News

Evoke Pharma, Inc. (NASDAQ:EVOK)

Shares of Evoke Pharma, Inc. (NASDAQ: EVOK) exploded this morning on news that the U.S. Food and Drug Administration Evoke’s Gimoti is exempt from a human factors validation study requirement prior to submission of its New Drug Application. Gimoti is Evoke’s lead product candidate. It is a nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women.

EVOK shares ended Tuesday at $2.61, gapped up to open this morning at $4.00 on the news, and reached a high of $4.55 before retreating below the $4 handle. Volumes have been very heavy – 26 times normal. Of note may be the number of shares held short. Over 15% of the float is held as a short position. Also of note should be the 52-week trading range of Evoke Pharma, Inc. (NASDAQ: EVOK). EVOK is trading 67% below the 52-week high of $11.11, and 168% above the low of $1.35.

Solana Beach, CA-based Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) diseases. Evoke was established by experienced specialty pharmaceutical executives with a successful track record of acquiring, developing, registering, and marketing pharmaceutical products in the US.

Evoke Pharma, Inc. (NASDAQ: EVOK) has no reported sale. Since 2011 there have been annual EPS losses of $2.18, $1.80, $1.20, $2.20, and $1.87 (2015). Two firms, Rodman&Renshaw and Laidlaw, that follow Evoke Pharma, Inc. (NASDAQ: EVOK) upgraded their ratings on EVOK shares this year. Five firms follow Evoke Pharma, Inc. (NASDAQ: EVOK) – two analysts rate EVOK shares as a Strong Buy” while one each rate the shares as a “Buy”, “Hold”, and “Sell”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol EVOK
Last Price a/o 1:44 PM EST  $                      3.58
Average Volume                1,020,000
Market Cap (mlns)  $                    30.93
Sales (mlns) $0.00
Shares Outstanding (mlns) 11.85
Share Float (mlns) 9.5
Shortable No
Optionable No
Inside Ownership 32.37%
Short Float 15.29%
Short Interest Ratio 1.42
Quarterly Return 56.29%
YTD Return 29.21%
Year Return -8.10%

Agenus Inc. (NASDAQ:AGEN) Deal With Incyte Corp. (INCY) Looks Good

Agenus Inc. (NASDAQ:AGEN)

Shares of small-cap Agenus Inc. (NASDAQ:AGEN) are up, on heavy volumes, on news that Incyte Corporation (NASDAQ:INCY) has essentially substituted a development and commercialization agreement into what essentially amounts to a “Call” option on future revenues of Agenus’ drugs GITR and OX40. The new agreement gives all future development and commercialization responsibilities to Incyte. Agenus receives a $28 million up-front payment and royalty payments on 15% of global net sales. AGEN shares are up over 10%. The ongoing TIM-3 and LAG-3 antibody programs remain royalty-bearing programs, at tiered rates of 6 to 12 percent, with Incyte retaining exclusive world-wide clinical development and commercial responsibilities. Also released this morning was news that Incyte would buy 10 million shares of AGEN at $6/share.

Lexington, MA-based Agenus Inc. (NASDAQ:AGEN) discovers and develops cancer treatments that engage the body’s immune system. Incyte Corporation (NASDAQ:INCY), based in Wilmington, DE, is a $23 billion company discovers, develops, and commercializes proprietary therapeutics in oncology in the United States and internationally.

Agenus Inc. (NASDAQ:AGEN) has an impressive amount of product in their pipeline. Five drugs are in pre-clinical data gathering. Four are in Phase 1 clinical trials, one is in its Phase 2 clinical trial, and two are completing their Phase 3 trials.

In 2014 Agenus Inc. (NASDAQ:AGEN) reported sales of just $7 million but in 2015 that figure improved to $24.8 million. However AGEN shareholders have experienced EPS losses for the past five years – $1.21, $$0.51, $1.12, $0.71, and $1.13 in 2015. Four analysts cover AGEN and three rate the shares as a “Strong Buy” while one rates AGEN shares as a “Hold”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol AGEN
Last Price a/o 10:47 AM EST  $                      4.62
Average Volume                1,030,000
Market Cap (mlns)  $                  354.07
Sales (mlns) $24.60
Shares Outstanding (mlns) 85.94
Share Float (mlns) 81.86
Shortable Yes
Optionable Yes
Inside Ownership 1.60%
Short Float 15.21%
Short Interest Ratio 12.08
Quarterly Return -20.16%
YTD Return 0.00%
Year Return 45.58%

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Massive Volumes But No Bump?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Massive volumes are being traded on Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH). Average daily volume is around 1.7 million shares but already thirty minutes into trading over 1 million shares have traded hands on the NASDAQ. AUPH shares closed yesterday at $3.62, opened this morning at $3.75 and hit a high of $3.78.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a late-stage biopharmaceutical company providing products engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need. Currently in Aurinia’s pipeline is Voclosporin – that has the potential to improve near- and long-term outcomes in lupus nephritis (LN). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

This morning Canadian-based Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced results of their supportive Phase 1 clinical study of Voclosporin. In their press release, Lawrence Mandt, VP of Regulatory and Quality of Aurinia stated “Additionally, the data support the use of the 23.7mg BID voclosporin dose in our global Phase 3 study in both Japanese and non-Japanese patients. We look forward to sharing our findings with the Japanese Pharmaceuticals and Medical Devices Agency in Q2 and confirming our path forward for regulatory submission in Japan.” The company’s Phase 3 clinical trial is supposed to begin in Q2, 2017.

AUPH was trading close to $2 at the end of 2016. Since then they replaced their CEO and AUPH shares have responded by rising over 70%. Investors should be reminded that Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has only one drug in its current pipeline. While the news of its clinical trials has been positive, there are no revenues on the horizon until, if and when, the company is able to commercialize Voclosporin. This is likely the reason AUPH is experiencing such huge volumes but is getting little price traction. The market appears to be telling buyers that greater financial certainty of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is required before higher levels are seen.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol AUPH
Last Price a/o 8:55 AM EST  $                      3.70
Average Volume                1,700,000
Market Cap (mlns)  $                  140.43
Sales (mlns) $0.20
Shares Outstanding (mlns) 38.79
Share Float (mlns) 22.43
Shortable Yes
Optionable Yes
Inside Ownership 0.00%
Short Float 11.73%
Short Interest Ratio 1.54
Quarterly Return 22.71%
YTD Return 72.38%
Year Return 60.18%

Cesca Therapeutics Inc. (NASDAQ:KOOL) Trying to Right the Ship – Mission Impossible?

Cesca Therapeutics Inc. (NASDAQ:KOOL)

Micro-Cap Cesca Therapeutics Inc. (NASDAQ:KOOL) released earnings after the regular session closed yesterday and seemed to blame some material expenses on the departure of their ex-CEO.

“The increase was primarily due to the termination of our former chief executive officer in November and legal fees associated with the SynGen litigation, partially offset by lower personnel costs.”

“The increase in net loss was primarily due to the termination of our former chief executive officer and legal fees associated with the SynGen litigation, partially offset by improved gross profit margin as already described.”

A deeper look into Cesca reveals more concerns than a simple employment separation.

In January of 2016, Cesca Therapeutics Inc. (NASDAQ:KOOL) received needed financing from Boyalife Group in order to continue operations.  (BoyaLife & INCOSC is jointly initiated by seven domestically and internationally well-known institutions including Peking University, CAS, the Roslin Institute and the Scottish Centre for Regenerative Medicine.) $2.5 million in KOOL shares (priced at $3.40/share) were placed with BoyalifeGroup as well as a $12.5 million with a 22% interest rate.

In March Cesca Therapeutics Inc. (NASDAQ:KOOL) went through a reverse 1:20 stock split.

In August BoyaLife converted the note into 6,102,941 common shares and became Cesca Therapeutics Inc. (NASDAQ:KOOL) largest shareholder.

In October of 2014, Cesca Therapeutics Inc. (NASDAQ: KOOL) announced it intended to embark on a nationwide search for a new Chief Executive Officer. Robin C. Stracey, currently a member of the Company’s Board of Directors, would serve as Interim CEO pending the new hire.

In November of 2016, Cesca issued a press release announcing the removal of Robin Stracey from its board and the CEO position – also removed were two other Directors. The board of directors then nominated and appointed Dr. Xiaochun (Chris) Xu as the new Chairman of the board of directors of the Company as well as CEO.

Many claim that Cesca is in need of new stewardship. In 2015 the company achieved their lowest sales and EPS in the last five years. In 2012, Cesca Therapeutics Inc. (NASDAQ:KOOL) reported sale so f$19 million compared with the company’s $11.9 million in 2016. EPS for Kool shareholders was a loss of $6.09 in 2012 compared with an EPS loss of $7.57 in 2016. Cesca Therapeutics Inc. (NASDAQ:KOOL) filed its Q2 2017 Earnings Summary with the SEC. They listed less than $5,000 in cash, and cash equivalents.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol KOOL
Last Price a/o 8:17 AM EST  $                      3.50
Average Volume                    184,500
Market Cap (mlns)  $                    30.72
Sales (mlns) $12.90
Shares Outstanding (mlns) 9.63
Share Float (mlns) 3.32
Shortable Yes
Optionable No
Inside Ownership 0.00%
Short Float 13.82%
Short Interest Ratio 2.48
Quarterly Return 7.41%
YTD Return -7.54%
Year Return 1495.00%
Adamis Pharmaceuticals Corp (NASDAQ:ADMP)

Xoma Corporation (NASDAQ:XOMA) $25 Million Deal with BVP Partners Explained

XOMA Corporation (NASDAQ:XOMA)

XOMA Corporation (NASDAQ:XOMA) shares are up over 15% on heavy volumes. XOMA shares closed Friday at $4.03 and have reached as high as $4.80 in inter-day trading. Announced today was the direct placement of 1.2 million shares of common stock and 5,003 shares of convertible preferred stock. The buyer is Biotechnology Fund LP (BVP Partners L.P.) and some of its affiliates. The common and preferred shares are priced at $4.03 – each preferred share equals 1,000 common shares, so if converted the common shares would total 5,003,000. The preferred shares may be converted at anytime but are capped at 19.99% of the total outstanding shares.

Established in 1993, San Francisco, CA-based BVF Partners L.P. is a private investment firm that takes positions in public small-cap biotechnology companies. Since June, 2016, BVF Partners L.P. has invested in Fate Therapeutics, Tobira Therapeutics, and Pieris Therapeuctics.

XOMA Corporation (NASDAQ:XOMA) is a biotechnology company with a portfolio of therapeutic antibodies. The company’s product candidates are the result of its expertise in developing monoclonal antibodies, which have created opportunities to potentially treat a wide range of endocrine diseases. XOMA 358 is their lead product candidate. It has just initiated a Phase 2 study in congenital hypoglycemia patients. XOMA 129 has been developed to address acute hypoglycemia and pre-clinical trial data was presented in April of 2016.

EPS for XOMA shareholders has been bleak. Since 2011 EPS losses are as follows: $20.72, $21.99, $28.54, $7.13, and $3.50. Sales were $58.2 million in 2011, but Xoma Corporation (NASDAQ:XOMA) posted just $55.4 million in 2015 which was an improvement over the $18.9 million it posted in 2014. Four firms follow the Xoma Corporation (NASDAQ:XOMA). All four rate XOMA shares as a “Hold” with a consensus price target of $9.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol XOMA
Last Price a/o 1:34 PM EST  $                      4.70
Average Volume                      77,150
Market Cap (mlns)  $                    24.78
Sales (mlns) $53.20
Shares Outstanding (mlns) 6.15
Share Float (mlns) 5.74
Shortable Yes
Optionable Yes
Inside Ownership 1.20%
Short Float 9.47%
Short Interest Ratio 7.04
Quarterly Return -28.55%
YTD Return -4.50%
Year Return -73.83%